SCHEMBL15560633

SCHEMBL15560633

O=C(COc1ccc(/C(Cc2ccccc2)=N/OCc2ccc(Cl)cc2)cc1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
HPGD P15428 2/20 0.60
KDM4E B2RXH2 1/20 0.60
LMNA P02545 1/20 0.60
HTT P42858 1/20 0.60
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GPR183 P32249 1/20 0.59
FKBP1A P62942 7/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
ENPP2 Q13822 1/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 1/20 0.48
USP2 O75604 2/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15560634 1.00 ALDH1A1 (0.60) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15543992 0.94 ALDH1A1 (0.62) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15543990 0.94 ALDH1A1 (0.62) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15561016 0.91 FKBP1A (0.60) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15543994 0.91 FKBP1A (0.60) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15543996 0.91 FKBP1A (0.60) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15561014 0.91 FKBP1A (0.60) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL16468221 0.91 FKBP1A (0.57) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL16468222 0.91 FKBP1A (0.57) ALDH1A1HPGDKDM4ELMNAHTT
SCHEMBL15543208 0.89 ALDH1A1 (0.53) ALDH1A1HPGDKDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US claimed
EP-2864309-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES Cadila Healthcare Limited (IN) 2015-04-29 EP disclosed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US disclosed
WO-2014002105-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LIMITED (IN) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES PCSK9, HMGCR, CETP ALDH1A1 1508/4885HPGD 847/4885KDM4E 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.